119 related articles for article (PubMed ID: 17682432)
1. [Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion].
Usui N; Miyamura K; Arai A; Motomura S; Yokoyama M
Nihon Naika Gakkai Zasshi; 2007 Jul; 96(7):1434-55. PubMed ID: 17682432
[No Abstract] [Full Text] [Related]
2. [Chronic myeloproliferative diseases. Current therapeutic standards and new developments].
Krause SW; Mackensen A
Internist (Berl); 2008 Dec; 49(12):1452-7. PubMed ID: 18985309
[TBL] [Abstract][Full Text] [Related]
3. [Myeloproliferative neoplasms (including chronic myeloid leukemia)].
Fukushima N; Ichinohe T; Kimura S
Rinsho Ketsueki; 2012 Jan; 53(1):59-70. PubMed ID: 22374526
[No Abstract] [Full Text] [Related]
4. Current treatment of myeloproliferative neoplasias: three scenarios.
Xicoy B; Zamora L
Med Clin (Barc); 2020 Feb; 154(4):131-133. PubMed ID: 31351663
[No Abstract] [Full Text] [Related]
5. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
6. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
7. Imatinib and ruxolitinib association: first experience in two patients.
Iurlo A; Gianelli U; Rapezzi D; Cattaneo D; Fermo E; Binda F; Santambrogio E; Bucelli C; Cortelezzi A
Haematologica; 2014 Jun; 99(6):e76-7. PubMed ID: 24633869
[No Abstract] [Full Text] [Related]
8. [Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia].
Jomen W; Kuroda H; Matsuno T; Sato M; Yamada M; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Kato J; Nojiri S
Rinsho Ketsueki; 2014 Mar; 55(3):360-5. PubMed ID: 24681942
[TBL] [Abstract][Full Text] [Related]
9. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Michiels JJ; Pich A; De Raeve H; Gadisseur A
Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
[No Abstract] [Full Text] [Related]
10. 3. Imatinib therapy in chronic myelogenous leukemia.
Jinnai I
Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
[No Abstract] [Full Text] [Related]
11. [Chronic myeloproliferative syndromes].
de Ozalla CB; García Suárez J
Rev Clin Esp; 1999 Apr; 199 Suppl 1():28-36. PubMed ID: 10422448
[No Abstract] [Full Text] [Related]
12. Which TKI should be recommended as initial treatment for CML in chronic phase?
Schiffer CA
Oncology (Williston Park); 2012 Oct; 26(10):912, 914. PubMed ID: 23175997
[No Abstract] [Full Text] [Related]
13. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
14. Front-line TKI therapy for chronic-phase CML: the luxury of choice.
Shah NP
Oncology (Williston Park); 2012 Oct; 26(10):908, 910, 912. PubMed ID: 23175996
[No Abstract] [Full Text] [Related]
15. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Quintás-Cardama A; Kantarjian H; Cortes J
Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
[No Abstract] [Full Text] [Related]
16. Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
Mauro MJ
Curr Treat Options Oncol; 2007 Aug; 8(4):287-95. PubMed ID: 18157514
[No Abstract] [Full Text] [Related]
17. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
18. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
[No Abstract] [Full Text] [Related]
19. The management of elderly patients with myeloproliferative disorders.
Tura S
Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
[No Abstract] [Full Text] [Related]
20. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
[No Abstract] [Full Text] [Related]
[Next] [New Search]